Physician profile

Michael Gottlieb

Internal Medicine · Pasadena, CA

NPI 1871506808

$191,257.71

in general payments reported to CMS, 2019-2025

48 companies · $223 in 2025

The $223 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$5,580.00
Consulting Fee$2,450.00
Food and Beverage$1,456.94

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Viiv Healthcare Company $77,415.87 2019-2022
Merck Sharp & Dohme LLC $69,258.20 2019-2025 Delstrigo, Pifeltro
Gilead Sciences, INC. $17,345.99 2019-2025 Veklury
Janssen Products, LP $11,416.77 2019
Theratechnologies INC. $5,161.37 2019-2023 Trogarzo, Egrifta
Emd Serono, INC. $5,033.25 2019-2023 Serostim
Abbvie INC. $824.40 2019-2025
Napo Pharmaceuticals INC $669.09 2019-2025 Mytesi
Janssen Biotech, INC. $646.98 2019-2023 Symtuza
Janssen Scientific Affairs, LLC $550.66 2019-2020
Antares Pharma, INC. $227.38 2019-2023 Nocdurna, Xyosted, Tlando
Amgen INC. $222.87 2019-2022
Allergan, INC. $222.18 2019-2020
Bausch Health US, LLC $193.95 2020-2023 Aplenzin
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $179.24 2019-2022
Show all 48 companies
CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $163.30 2019-2023 Wegovy
Takeda Pharmaceuticals U.S.A., INC. $146.64 2019-2022
Pfizer INC. $144.81 2019-2025
Lilly USA, LLC $124.28 2019-2022
Paratek Pharmaceuticals, INC. $117.91 2020-2021
Alkermes, INC. $114.67 2023 Lybalvi, Aristada
Sunovion Pharmaceuticals INC. $114.34 2019
Eisai INC. $96.84 2020-2021
Glaxosmithkline, LLC. $82.42 2019-2021
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $68.91 2023-2024 Caplyta
Amarin Pharma, INC. $64.40 2019-2021
Kci USA, INC. $61.87 2020
Almatica Pharma LLC $60.80 2022-2023 Loreev Xr
Nestle Healthcare Nutrition INC. $59.83 2021-2022
Novartis Pharmaceuticals Corporation $45.60 2022
Csl Behring $36.35 2021-2022
Dynavax Technologies Corporation $34.74 2021
Teva Pharmaceuticals USA, INC. $34.06 2019
Janssen Pharmaceuticals, INC $32.79 2024 Spravato
Idorsia Pharmaceuticals US INC $29.66 2023 Quviviq
Boston Scientific Corporation $26.50 2020
Acerus Pharmaceuticals Corporation $24.73 2021
Hologic Sales and Service, LLC $24.05 2022
Boehringer Ingelheim Pharmaceuticals, INC. $23.09 2021
Grifols USA, LLC $22.66 2019
Abbott Laboratories $21.87 2021
Jazz Pharmaceuticals INC. $20.79 2021
Sanofi Pasteur INC. $19.89 2019
Astrazeneca Pharmaceuticals LP $17.17 2023 Farxiga
Biohaven Pharmaceuticals, INC. $15.02 2021
Metuchen Pharmaceuticals $14.48 2019
Actelion Pharmaceuticals US, INC. $13.41 2019
Redhill Biopharma INC. $11.63 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Gottlieb

$191,257.71

in general payments reported 2019-2025

Years
2019-2025
Top company
Viiv Healthcare Company
Context
The $223 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/220382/michael-gottlieb

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.